source
- Q&A: Seaport CEO and CSO on learning from Karuna and the future of CNS researchSeaport Therapeutics began trading as a public company on Friday after executives rang the Nasdaq’s opening bell. Shares rose {$SPTX} more than 20%. With a team largely made up of Karuna Therapeuti…Endpoints · 2mo ago↗ source
- Summit’s ‘self-inflicted’ stumble; Esperion’s take-private dealSummit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast c…BioPharma Dive · 2mo ago↗ source
- Moderna sees revenue bump from international COVID vaccine salesThe company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.